DDInter485 DDInter1055
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Enoxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gemifloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Sparfloxacin
Sparfloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Moxifloxacin
Moxifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Daunorubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Lomefloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Gatifloxacin
Gatifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Daunorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Levofloxacin
Daunorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is bound by {v} (Compound) Levofloxacin
Daunorubicin {u} (Compound) downregulates {v} (Gene) GPATCH8
GPATCH8 {u} (Gene) is upregulated by {v} (Compound) Levofloxacin
Daunorubicin {u} (Compound) upregulates {v} (Gene) KIAA0196
KIAA0196 {u} (Gene) is downregulated by {v} (Compound) Levofloxacin
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Levofloxacin (Compound)
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Daunorubicin may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Levofloxacin (Compound)
Daunorubicin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Levofloxacin (Compound)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Levofloxacin (Compound)
Daunorubicin may lead to a major life threatening interaction when taken with Gatifloxacin and Gatifloxacin (Compound) resembles Levofloxacin (Compound)
Daunorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Levofloxacin (Compound)
Daunorubicin (Compound) binds TOP2A (Gene) and Daunorubicin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Levofloxacin (Compound)
Daunorubicin (Compound) downregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Levofloxacin (Compound)
Daunorubicin (Compound) upregulates KIAA0196 (Gene) and KIAA0196 (Gene) is downregulated by Levofloxacin (Compound)